Related Experiment Video
Updated: Sep 2, 2026

Measuring Single-Cell Aging with an Imaging-based Biomarker of Chromatin and Epigenetic Aging
Published on: January 30, 2026
Assessing Differences Between Epigenetic versus Chronologic Age for Cardiovascular Risk Assessments in the United
Ramzi Ibrahim1, Balaji Tamarappoo1, Kwan Lee1
1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ.
Abstract:
Background: Epigenetic clocks derived from DNA methylation estimate biological aging and have been associated with cardiometabolic death. We evaluated whether substituting epigenetic age for chronologic age within PREVENT altered associations with all-cause and cardiovascular mortality or improved discrimination. Methods: We analyzed National Health and Nutrition Examination Survey 1999-2002 data linked to National Death Index follow-up through December 31, 2019. Adults aged 50-79 years without baseline cardiovascular disease and with DNA methylation data were included. PREVENT is a primary-prevention framework incorporating demographic, cardiometabolic, renal, and treatment factors. Exposures were PREVENT estimates calculated using chronologic age or 8 epigenetic ages substituted for chronologic age, with other inputs unchanged. Survey weighted Cox models estimated associations with all-cause and cardiovascular mortality per 5-percentage-point higher predicted risk. Weighted Harrell C statistics assessed discrimination; 95% CIs were obtained by bootstrap resampling. Results: The cohort included 1,516 participants (weighted mean age, 60.3 years; SD, 8.0) with a mean follow-up of 17.35 years; 507 participants died, including 140 cardiovascular deaths. Each 5-percentage-point increase in chronologic PREVENT risk was associated with all-cause mortality (HR, 1.57; 95% CI, 1.45-1.70) and cardiovascular mortality (HR, 1.66; 95% CI, 1.501.84). Biologic variants showed similar associations for all-cause mortality (HR range, 1.391.57) and cardiovascular mortality (HR range, 1.47-1.67). Chronologic PREVENT showed higher discrimination for all-cause mortality (C, 0.74; 95% CI, 0.72-0.77) than biologic variants (C range, 0.66-0.73) and for cardiovascular mortality (C, 0.78; 95% CI, 0.73-0.84) than biologic variants (C range, 0.71-0.77). Conclusions: Biologic PREVENT variants were associated with mortality but did not improve discrimination compared with chronologic PREVENT, suggesting biological aging metrics may complement rather than replace chronological age in cardiovascular risk prediction.
Related Concept Videos
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Longitudinal Research
Longitudinal Studies
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
